Comparative Pharmacology
Head-to-head clinical analysis: GLUCOPHAGE XR versus QTERNMET XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLUCOPHAGE XR versus QTERNMET XR.
GLUCOPHAGE XR vs QTERNMET XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Biguanide; decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Qternmet XR is a combination of saxagliptin (a DPP-4 inhibitor) and metformin (a biguanide). Saxagliptin increases incretin levels (GLP-1, GIP) by inhibiting DPP-4, enhancing glucose-dependent insulin secretion and suppressing glucagon release. Metformin decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity.
Metformin XR: initial 500 mg orally once daily with evening meal, increase by 500 mg weekly; max 2000 mg per day (as XR, given once or divided twice daily).
Adults: 500 mg orally once daily with the evening meal, increase by 500 mg every 1-2 weeks up to a maximum of 2000 mg once daily. For extended-release (XR) formulation, titrate from 500 mg to 2000 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 17.6 hours (range 9.1–40.6 hours); clinical context: reflects slow absorption from extended-release matrix; accumulation occurs with renal impairment
Terminal half-life: 4–6 hours; clinically relevant for dosing interval (every 6–8 hours) and steady-state achievement within 24 hours.
Renal: 90% unchanged; fecal: minimal (<5%)
Renal: 90% unchanged via glomerular filtration and tubular secretion; fecal: 10%.
Category C
Category C
Biguanide Antidiabetic
Biguanide Antidiabetic